Alternate day pomalidomide retains anti‐myeloma effect with reduced adverse events and evidence of <i>in vivo</i> immunomodulation
Matthew Streetly(King's College - North Carolina), Stephen Schey(University College Hospital), Kylie Gyertson(University College London Hospitals NHS Foundation Trust), Jerome B. Zeldis(University of California, Davis), Yvonne Daniel(St Thomas' Hospital), Majid Kazmi
Cited by 127
Related Papers
Efficacy of Lenalidomide in Myelodysplastic Syndromes
|New England Journal of Medicine|2005|874
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation
|Blood|2000|502
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease
|Blood|2018|421
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
|The Lancet|2020|366
Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma
|Journal of Clinical Oncology|2004|315